You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sodium-glucose transport protein 2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,

Not yet recruiting
  • Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
  • (no location specified)
Jan 22, 2023

Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)

Recruiting
  • Heart Failure
  • Reduced Ejection Fraction Heart Failure
  • Empagliflozin 10 MG
  • Dapagliflozin 10 MG
  • DamanhÅ«r, Elbehairah, Egypt
    Damanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Cardiorenal Syndrome Trial in New Haven (Dapagliflozin)

Not yet recruiting
  • Cardiorenal Syndrome
  • New Haven, Connecticut
    Yale New Haven Hospital
Oct 26, 2023

NASH - Nonalcoholic Steatohepatitis, Diabetes, Type 2 Trial in Worldwide (IVA337, Placebo, Empagliflozin)

Recruiting
  • NASH - Nonalcoholic Steatohepatitis
  • Diabetes Mellitus, Type 2
  • Homewood, Alabama
  • +40 more
Jan 23, 2023

Chronic Kidney Disease, Diabetes, Type 2, Hypertension Trial in Genova (Dapagliflozin 10mg Tab, Placebo)

Recruiting
  • Chronic Kidney Disease
  • +2 more
  • Dapagliflozin 10mg Tab
  • Placebo
  • Genova, GE, Italy
    IRCCS Ospedale Policlinico San Martino
Aug 10, 2023

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))

Not yet recruiting
  • Metabolic Associated Fatty Liver Disease
  • dapagliflozin (Forxiga)
  • (no location specified)
Mar 13, 2023

Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)

Completed
  • Healthy Volunteers
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular

Not yet recruiting
  • SGLT2 Inhibitiors Remodeling Effect
  • Chronic Heart Disease
  • Sodium-glucose cotransporter 2 inhibitor
  • (no location specified)
Nov 14, 2023

Cystinuria Trial in San Francisco (Dapagliflozin)

Not yet recruiting
  • Cystinuria
  • San Francisco, California
    University of California, San Francisco
Sep 13, 2022

Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan

Recruiting
  • Heart Failure
  • +2 more
  • SGLT2 inhibitor
  • Roma, RM, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023

Tricuspid Regurgitation Trial in Seoul (Dapagliflozin Propanediol Hydrate 12.3 mg)

Recruiting
  • Tricuspid Regurgitation
  • Dapagliflozin Propanediol Hydrate 12.3 mg
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 9, 2023

Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)

Completed
  • Fatty Liver Disease
  • Canagliflozin 100mg
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Feb 28, 2023

SGLT2 Inhibition in Heart Failure

Recruiting
  • Heart Failure
  • Sodium-glucose cotransporter 2 inhibitor
  • Belfast, United Kingdom
    Belfast Health and Social Care Trust
Nov 15, 2023

Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

Not yet recruiting
  • Acute Kidney Injury
  • +2 more
  • Dapagliflozin 10 MG Oral Tablet [Farxiga]
  • Placebo
  • Amsterdam, Netherlands
  • +5 more
Oct 18, 2022

Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Porto, Portugal
  • +3 more
Aug 9, 2023

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Diabetes, Type 2, Endothelial Dysfunction Trial in Boston (Dapagliflozin, Placebo)

Recruiting
  • Diabetes Mellitus, Type 2
  • Endothelial Dysfunction
  • Boston, Massachusetts
    BU School of Medicine Evans 748
Jun 1, 2022

Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)

Not yet recruiting
  • Sleep Apnea
  • Ertugliflozin 15 mg
  • Placebo
  • New Haven, Connecticut
  • +1 more
Jan 24, 2023

SGLT-2 Inhibitors in the Treatment of Ascites

Recruiting
  • Ascites Hepatic
  • +2 more
  • SGLT2 inhibitor
  • Palermo, Italy
  • +1 more
Aug 11, 2023

Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)

Not yet recruiting
  • Fatty Liver, Nonalcoholic
  • SGLT2 inhibitor
  • (no location specified)
Oct 31, 2023

Myocardial Ischemia Trial (Dapagliflozin 10mg Tab, Placebo)

Not yet recruiting
  • Myocardial Ischemia
  • Dapagliflozin 10mg Tab
  • Placebo
  • (no location specified)
Feb 27, 2023